Camlin Fine Sciences Q1FY27 Revenue Up 27.5% YoY

Revenue from continuing operations reached Rs 5,198.8 mn in Q1 FY27, representing 27.5% YoY growth and the highest ever quarterly revenue.
Gross margin was 41.2% in Q1 FY27, compared to 48.5% in Q4 FY26, impacted by higher raw material prices, limited pass-through, and liquidity issues.
The operating environment was characterized by continued impact from higher raw material prices, higher logistics costs, longer delivery times, and an elongated working capital cycle.
Key drivers included strong performance across all segments: Straights, Blends, and Aroma Ingredients.

Straights: Revenue of Rs 927 mn, up 41% YoY despite high competition.
Blends: Revenue up 35% YoY; Vinpai contributed Rs 247 mn for the quarter.
Aroma: Revenue grew 37% YoY with steady realizations and volumes of Vanillin.
Explanation of significant changes: Growth was driven by strong demand across all geographies and the stabilization of recent acquisitions (Vitafor & Vinpai).

Revenue: Rs 5,198.8 mn (Q1 FY27)
EBITDA: Rs 92.7 mn
Adjusted EBITDA*: Rs 176.4 mn
PAT: Rs (318.0) mn (loss)
EPS: Not Specified
Margins: EBITDA Margin 1.8%; Adjusted EBITDA Margin 3.4%
YoY/QoQ comparison: Revenue increased from Rs 4,077.2 mn in Q1 FY26 and Rs 4,248.1 mn in Q4 FY26. Adjusted EBITDA decreased from Rs 202.9 mn in Q1 FY26 and Rs 211.9 mn in Q4 FY26.
Drivers of financial performance: Higher revenue growth was offset by increased raw material consumption (Rs 3,056.8 mn vs Rs 2,256.9 mn in Q1 FY26) and an exceptional item of Rs 111.1 mn (shortfall in settlement of insurance claim for fire at Brazil unit).
Comparison to market estimates: Not Specified
Key Risks: Raw material price hikes, regulatory risks, lingering conflict situation impacting transit time and operating cycle, and inflationary environment.

Investments in Innovation: Scale Xtendra®, NaSure®, Enzentia® across food, functional ingredients, and animal nutrition; Expand performance nutrition, gut health and Vitafor solutions; Grow Brazil biodiesel; Expand presence in high performance segments; Build on Diphenol platform.
Expected impact on growth: Aim to breakeven in Aroma segment in coming quarters; Growth momentum to continue across all geographies.
Strategic Rationale: Outpace industry growth through innovation and wider reach; Deepen customer partnerships and enter aquaculture and water treatment; Optimizing supply chain and cost structures.

Macro/Industry Trends: Market growth in specialty ingredients; raw material price fluctuations; regulatory changes; higher logistics costs.
Impact on Company: Macro trends are affecting margins (159 bps negative impact on underlying EBITDA), revenue growth, and cost structure (elongated working capital cycle).

Strategic Outlook: "Blends: Growth momentum to continue across all geographies. Vitafor & Vinpai to stabilise. Aroma: Improving growth trajectory of Vanillin with steady realisations. Aim to breakeven in coming quarters."
FY Guidance: Not Specified
Market Share Targets: Not Specified
Risks and Opportunities: "Lingering conflict situation may hamper transit time, operating cycle, and inflationary environment in the near term."

Environmental: Transitioned to real-time environmental visibility through online installations; undertook thermal insulation program to minimize heat loss and optimize energy.
Social: Renovated Occupational Health Centre (OHC); enhanced medical surveillance; completed SEDEX audits; continued investment in workplace health, safety and inclusivity.
Governance: Diverse and experienced Board; regular Board sessions; strengthened risk-management practices; progressed FY2025–26 Global Reporting Initiative (GRI) assignment.